These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The history of the development and changes of quinolone antibacterial agents]. Takahashi H; Hayakawa I; Akimoto T Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768 [TBL] [Abstract][Full Text] [Related]
3. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Martin SJ; Jung R; Garvin CG Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723 [TBL] [Abstract][Full Text] [Related]
4. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ Drugs; 2002; 62(1):13-59. PubMed ID: 11790155 [TBL] [Abstract][Full Text] [Related]
5. The antibacterial activity of fluoroquinolone derivatives: An update (2018-2021). Jia Y; Zhao L Eur J Med Chem; 2021 Nov; 224():113741. PubMed ID: 34365130 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of the fluoroquinolones: focus on levofloxacin. Liu HH Drug Saf; 2010 May; 33(5):353-69. PubMed ID: 20397737 [TBL] [Abstract][Full Text] [Related]
7. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin]. Hoepelman I Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354 [TBL] [Abstract][Full Text] [Related]
8. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499 [TBL] [Abstract][Full Text] [Related]
9. Levofloxacin and sparfloxacin: new quinolone antibiotics. Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064 [TBL] [Abstract][Full Text] [Related]
10. The safety profile of the fluoroquinolones. Bertino J; Fish D Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507 [TBL] [Abstract][Full Text] [Related]
11. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. Turner AK; Nair S; Wain J J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934 [TBL] [Abstract][Full Text] [Related]
12. The fluoroquinolone antibacterials: past, present and future perspectives. Appelbaum PC; Hunter PA Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413 [TBL] [Abstract][Full Text] [Related]
13. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals. Yarrington ME; Anderson DJ; Dodds Ashley E; Jones T; Davis A; Johnson M; Lokhnygina Y; Sexton DJ; Moehring RW Infect Control Hosp Epidemiol; 2019 Nov; 40(11):1297-1300. PubMed ID: 31474240 [TBL] [Abstract][Full Text] [Related]
15. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration]. Sirvent E; Ruiz M; Rodríguez JC; Royo G Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384 [TBL] [Abstract][Full Text] [Related]
16. The quinolones: decades of development and use. Emmerson AM; Jones AM J Antimicrob Chemother; 2003 May; 51 Suppl 1():13-20. PubMed ID: 12702699 [TBL] [Abstract][Full Text] [Related]